АДИПОНЕКТИН: БЛАГОПРИЯТНОЕ ВОЗДЕЙСТВИЕ НА МЕТАБОЛИЧЕСКИЕ И СЕРДЕЧНО-СОСУДИСТЫЕ НАРУШЕНИЯ


https://doi.org/10.18705/1607-419X-2013-19-1-84-96

Полный текст:


Аннотация

Посвящается памяти моей Учительницы Янины Владимировны Благосклонной ьский институт экспериментальной медицины» СЗО РАМН (ФГБУ «НИИ ЭМ» СЗО РАМН)

Об авторах

Н. С. Парфенова
Научно-исследовательский институт экспериментальной медицины СЗО РАМН, Санкт-Петербург
Россия

Кандидат медицинских наук, старший научный сотрудник отдела биохимии ФГБУ «Научно-исследовательский институт экспериментальной медицины» СЗО РАМН (ФГБУ «НИИ ЭМ» СЗО РАМН). 

Контактная информация: ФГБУ «Научно-исследовательский институт экспериментальной медицины» СЗО РАМН, ул. Академика Павлова, д. 12, Санкт-Петербург, Россия, 197376. Тел.: 8 (812) 234–93–41. E-mail: nina.parf@mail.ru (Парфенова Нина Соломоновна)



Д. А. Танянский
Научно-исследовательский институт экспериментальной медицины СЗО РАМН, Санкт-Петербург
Россия
Кандидат медицинских наук, старший научный сотрудник отдела биохимии ФГБУ «НИИ ЭМ» СЗО РАМН.


Список литературы

1. Matsuzawa Y. Establishment of a concept of visceral fat syndrome and discovery of adiponectin // Proc. Jpn. Acad. Ser. B. Phys. Biol. Sci. — 2010. — Vol. 86, № 2. — P. 131–141.

2. Matsuzava Y. Adipocytokines, insulin resistance and main non-communicable diseases // In: Hormones, age and cancer. Ed. by L. Berstein. — St Petersburg: «Nauka», 2005. — P. 159–169.

3. Ohashi K., Ouchi N., Matsuzawa Y. Adiponectin and hypertension // Am. J. Hypertens. — 2011. — Vol. 24, № 3. — P. 263–269.

4. Matsuzawa Y. The metabolic syndrome and adipocytokines // Expert Rev. Clin. Immunol. — 2007. — Vol. 3, № 1. — P. 39–46.

5. Goldstein B.J., Scalia R.G., Ma X.L. Protective vascular and myocardial effects of adiponectin // Nat. Clin. Pract. Cardiovasc. Med. — 2009. — Vol. 6, № 1. — P. 27–35.

6. Ziemke F., Mantzoros C.S. Adiponectin in insulin resistance: lessons from translational research // Am. J. Clin. Nutr. — 2010. — Vol. 91, № 1. — P. 2585–2615.

7. Maeda K., Okubo K., Shimomura I. et al. cDNA cloning and expression of a novel adipose specifi c collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1) // Biochem. Biophys. Res. Commun. — 1996. — Vol. 221, № 2. — P. 286–289.

8. Scherer P.E., Williams S., Fogliano M. et al. A novel serum protein similar to C1q produced exclusively in adipocytes // J. Biol. Chem. — 1995. — Vol. 270, № 45. — P. 26746–26749.

9. Liu M., Liu F. Transcriptional and post-translational regulation of adiponectin // Biochem. J. — 2009. — Vol. 425, № 1. — P. 41–52.

10. Deepa S.S., Dong L.Q. APPL1: role in adiponectin signaling and beyond // Am. J. Physiol. Endocrinol. Metab. — 2009. — Vol. 296, № 1. — Р. E22–Е36.

11. Kadowaki T., Yamauchi T. Adiponectin and adiponectin receptors // Endocr. Rev. — 2005. — Vol. 26, № 3. — P. 439–451.

12. Matsuzawa Y. Adiponectin: a key player in obesity related disorders // Curr. Pharm. Des. — 2010. — Vol. 16, № 17. — P. 1896–1901.

13. Беляева О.Д., Баженова Е.А., Березина А.В. и др. Уровень адипонектина, показатели липидного и углеводного обменов у пациентов с абдоминальным ожирением // Артериальная гипертензия. — 2009. — Т. 15, № 3. — C. 309–313. / Belyaeva O.D., Bazhenova E.A., Berezina A.V. et al. Adiponectin

14. levels, lipid profi le and glucose metabolism in patients with abdominal obesity // Arterial Hypertension [Arterialnaya Gipertenziya]. — 2009. — Vol. 15, № 3. — Р. 309–313 [Russian].

15. Matsuzawa Y. The metabolic syndrome and adipocytokines // FEBS Letters. — 2006. — Vol. 580, № 12. — P. 2917–2921.

16. Halleux C.M., Takahashi M., Delporte M. et al. Secretion of adiponectin and regulation of apM 1 gene expression in human visceral adipose tissue // Biochem. Biophys. Res. Commun. — 2001. — Vol. 288, № 5. — P. 1102–1107.

17. Maeda N., Takahashi M., Funahashi T. et al. PPAR-γ gamma ligands increase expression and plasma concentration of adiponectin, an adipose-derived protein // Diabetes. — 2001. — Vol. 50, № 9. — P. 2094–2099.

18. Jorge M.L., de Oliveira V.N., Resende N.M. et al. The effects of aerobic, resistance, and combined exercise on metabolic control, infl ammatory markers, adipocytokines, and muscle insulin signaling in patients with type 2 diabetes mellitus // Metabolism. — 2011. — Vol. 60, № 9. — P. 1244–1252.

19. Hotta K., Funahashi T., Arita Y. et al. Plasma concentrations of a novel, adipose-specifi c protein, adiponectin, in type 2 diabetic patients // Arterioscle. Thromb. Vas. Biol. — 2000. — Vol. 20, № 6. — P. 1595–1599.

20. Wolfson N., Gavish D., Matas Z. et al. Relation of adiponectin to glucose tolerance status, adiposity, and cardiovascular risk factor load // Exp. Diabetes Res. — 2012. — Vol. 2012. — Article ID 250621. — doi: 10.1155/2012/250621.

21. Rubin D.A., Hackney A.C. Infl ammatory cytokines and metabolic risk factors during growth and maturation: influence of physical activity // Med. Sport Sci. — 2010. — Vol. 55. — P. 43–55.

22. Adamska A., Nikołajuk A., Karczewska-Kupczewska M. et al. Relationships between serum adiponectin and soluble TNF-α re-ceptors and glucose and lipid oxidation in lean and obese subjects // Acta Diabetol. — 2012. — Vol. 49, № 1. — P. 17–24.

23. Pyrzak B., Ruminska M., Popko K., Demkow U. Adiponectin as a biomarker of the metabolic syndrome in children and adolescents // Eur. J. Med. Res. — 2010. — Vol. 15, suppl. 2. — P. 147–151.

24. Lindsay R.S., Funahashi T., Hanson R.L. et al. Adiponectin protects against development of type 2 diabetes in the Pima Indians population // Lancet. — 2002. — Vol. 360, № 9326. — P. 57–58.

25. Maeda N., Shimomura I., Kishida K. et al. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30 // Nat. Med. — 2002. — Vol. 8, № 7. — P. 731–737.

26. Tomas E., Tsao T.S., Saha A.K. et al. Enhanced muscle fat oxidation and glucose transport by ACR30 globular domain: acetyl-CoA carboxylase inhibition and AMP-activated protein kinase activation // Proc. Natl. Acad. Sci. USA. — 2002. — Vol. 99, № 25. — P. 16309–16313.

27. Trotta P.A., Moura E.G., Franco J.G. et al. Blocking leptin action one week after weaning reverts most of the programming caused by neonatal hyperleptinemia in the adult rat // Horm. Metab. Res. — 2011. — Vol. 43, № 3. — P. 171–177.

28. Park J.E., Choi H.J., Kim I.K. et al. Infl uence of serum leptin levels on future overweight risk in Korean children // Nutr. Metab. Cardiovasc. Dis. — 2012. — Vol. 22, № 3. — P. 260–268.

29. Oana F., Takeda H., Matsuzawa. A. et al. KTO-7924, a beta3-adrenergic receptor agonist, reduces hyperglycemia, and protects beta-cells in the islets of Langerhans of db/db mice // Endocr. Res. — 2010. — Vol. 35, № 4. — P. 174–182.

30. Oana F., Takeda H., Matsuzawa A. et al. Adiponectin receptor 2 expression in liver and insulin resistance in db/db mice given a beta3-adrenoceptor agonist // Eur. J. Pharmacol. — 2005. — Vol. 518, № 1. — P. 71–76.

31. de Oliveira C., de Mattos A.B., Biz C., Oyama L.M., Ribeiro E.B., do Nascimento C.M. High-fat diet and glucocorticoid treatment cause hyperglycemia associated with adiponectin receptor alterations // Lipids Health Dis. — 2011. — Vol. 10. — P. 11.

32. Baudrand R., Campino C., Carvajal C.A. et al. Increased urinary glucocorticoid metabolites are associated with metabolic syndrome, hypoadiponectinemia, insulin resistance and β cell dysfunction // Steroids. — 2011. — Vol. 76, № 14. — P. 1575–1581.

33. Seifi S., Tabandeh M.R., Nazifi S. et al. Regulation of adiponectin gene expression in adipose tissue by thyroid hormones // J. Physiol. Biochem. — 2012. — Vol. 68, № 2. — P. 193–203.

34. Qin Y., Tian Y.P. Exploring the molecular mechanisms underlying the potentiation of exogenous growth hormone on alcohol-induced fatty liver diseases in mice // J. Transl. Med. — 2010. — Vol. 8. — P. 120.

35. Anan M., Uchihashi K., Aoki S. et al. A promising culture model for analyzing the interaction between adipose tissue and cardiomyocytes // Endocrinology. — 2011. — Vol. 152, № 4. — P. 1599–1605.

36. Парфенова Н.С. Метаболический синдром. Обзор // Рос. кардиол. журн. — 1998. — № 2. — C. 42–48. / Parfenova N.S. Metabolic syndrome. Review // Russian Cardiology Journal [Rossiyskiy Kardiologicheskiy Zhurnal]. — 1998. — № 2. — P. 42–48 [Russian].

37. Алмазов В.А., Благосклонная Я.В., Шляхто Е.В., Красильникова Е.И. Метаболический сердечно-сосудистый синдром. — СПб.: Издательство СПбГМУ, 1999. — 43 c. / Almazov V.A., Blagosklonnaya Ya.V., Shlyakhto E.V., Krasilnikova E.I. Metabolic cardiovascular syndrome. — St Petersburg: Publishing company of Pavlov St Petersburg State Medical University, 1999. — 43 p. [Russian].

38. Reddy K.J., Singh M., Bangit J.R. et al. The role of insulin resistance in the pathogenesis of atherosclerotic cardiovascular disease: an updated review // J. Cardiovasc. Med. (Hagerstown). — 2010. — Vol. 11, № 9. — P. 633–647.

39. Li F.Y., Cheng K.K, Lam K.S. et al. Сross-talk between adipose tissue and vasculature: role of adiponectin // Acta Physiol. (Oxf). — 2011. — Vol. 203, № 1. — P. 167–180.

40. Iwashima Y., Katsuya T., Ishikawa K. et al. Hypoadiponectinemia is an independent risk factor for hypertension // Hypertension. — 2004. — Vol. 43, № 6. — P. 1318–1323.

41. Chiu T.Y., Chen C.Y., Chen S.Y. et al. Indicators associated with coronary atherosclerosis in metabolic syndrome // Clin. Chim. Acta. — 2012. — Vol. 413, № 1–2. — P. 226–231.

42. Abdallah E., Waked E., Nabil M., El-Bendary O. Adiponectin and cardiovascular outcomes among hemodialysis patients // Kidney Blood Press. Res. — 2012. — Vol. 35, № 4. — P. 247–253.

43. Parul S.S., Mazumder M., Debnath B.C. Serum adiponectin in patients with coronary heart disease // Mymensingh Med. J. — 2011. — Vol. 20, № 1. — P. 78–82.

44. Garg M.K., Dutta M.K., Mahalle N. Adipokines (adiponectin and plasminogen activator inhhibitor-1) in metabolic syndrome // Indian J. Endocrinol. Metab. — 2012. — Vol. 16, № 1. — P. 116–123.

45. Lisowska A., Tycinska A., Knapp M. et al. Adiponectin — an independent marker of coronary artery disease occurrence rather than a degree of its advancement in comparison to the IMT values in peripheral arteries // Clin. Chim. Acta. — 2012. — Vol. 413, № 7–8. — P. 749–752.

46. Aso Y., Wakabayashi S., Terasawa T. et al. Elevation of serum high molecular weight adiponectin in patients with Type 2 diabetes and orthostatic hypotension: association with arterial stiffness and hypercoagulability // Diabet. Med. — 2012. — Vol. 29, № 1. — P. 80–87.

47. Pischon T., Hu F.B., Girman C.J. et al. Plasma total and high molecular weight adiponectin levels and risk of coronary heart disease in women // Atherosclerosis. — 2011. — Vol. 219, № 1. — P. 322–329.

48. Zoccali C., Mallamaci F., Tripepi G. et al. Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease // J. Am. Soc. Nephrol. — 2002. — Vol. 13, № 1. — P. 134–141.

49. Pischon T., Girman C.J., Hotamisligil G.S. et al. Plasma adiponectin levels and risk of myocardial infarction in men // J. Am. Med. Assoc. — 2004. — Vol. 291, № 14. — P. 1730–1737.

50. Kondo H., Shimomura I., Matsukawa Y. et al. Association of adiponectin mutation with type 2 diabetes: a candidate gene for the insulin resistance syndrome // Diabetes. — 2002. — Vol. 51, № 7. — P. 2325–2328.

51. Jaleel A., Aqil S., Jaleel S. Adipocytokines in subjects with and without ischemic cerebrovascular disease // Acta Neurol. Belg. — 2010. — Vol. 110, № 3. — P. 234–238.

52. Honda H., Ueda M., Kojima S. et al. Oxidized high-density lipoprotein as a risk factor for cardiovascular events in prevalent hemodialysis patients // Atherosclerosis. — 2012. — Vol. 220, № 2. — P. 493–501.

53. Konter J.M., Parker J.L., Baez E. et al. Adiponectin attenuates lipopolysaccharide-induced acute lung injury through suppression of endothelial cell activation // J. Immunol. — 2012. — Vol. 188, № 2. — P. 854–863.

54. Sun L., Hu F.B., Yu Z. et al. Lean body mass, interleukin 18, and metabolic syndrome in apparently healthy Chinese // PLoS One. — 2011. — Vol. 6, № 3. — P. e18104.

55. Larsson B., Svardsudd K., Welin L. et al. Abdominal adipose tissue distribution, obesity and risk of cardiovascular disease and death: 13 year follow up of participants in study ofmen born in 1913 // Br. Med. J. — 1984. — Vol. 288, № 6428. — P. 1401–1410.

56. Qi L., Menzaghi C., Salvemini L. et al. Novel locus FER is associated with serum HMW adiponectin levels // Diabetes. — 2011. — Vol. 60, № 8. — P. 2197–2201.

57. Xu A., Wang Y., Lam K.S., Vanhoutte P.M. Vascular actions of adipokines molecular mechanisms and therapeutic implications // Adv. Pharmacol. — 2010. — Vol. 60. — P. 229–255.

58. Mangge H., Almer G., Truschnig-Wilders M. et al. Inflammation, adiponectin, obesity and cardiovascular risk // Curr. Med. Chem. — 2010. — Vol. 17, № 36. — P. 4511–4520.

59. Vaiopoulos A.G., Marinou K., Christodoulides C., Koutsilieris M. The role of adiponectin in human vascular physiology // Int. J. Cardiol. — 2012. — Vol. 155, № 2. — P. 188–193.

60. Lautamaki R., Ronnemaa T., Huupponen R. et al. Low serum adiponectin is associated with high circulating oxidized low-dencity lipoprotein in patients with type 2 diabetes mellitus and coronary artery desease // Metabolism. — 2007. — Vol. 56, № 7. — P. 881–886.

61. Otani H. Oxidative stress as pathogenesis of cardiovascular risk associated with metabolic syndrome // Antioxid. Redox. Signal. — 2011. — Vol. 15, № 7. — P. 1911–1926.

62. Ouedraogo R., Wu X., Xu S.Q. et al. Adiponectin suppression of high-glucose-induced reactive oxygen species in vascular endothelial cells: evidence for involvement of a cAMP signaling pathway // Diabetes. — 2006. — Vol. 55, № 6. — P. 1840–1846.

63. Goldstein B.J. Scalia R. Adipokines and vascular disease in diabetes // Curr. Diab. Rep. — 2007. — Vol. 7, № 1. — P. 25–33.

64. Zhu W., Cheng K.K., Vanhoutte P.M. et al. Vascular effects of adiponectin: molecular mechanisms and potential therapeutic intervention // Clin. Sci. (Lond) — 2008. — Vol. 114, № 5. — P. 361–374.

65. Okamoto Y., Kihara S., Ouchi N. et al. Adiponectin reduces atherosclerosis in apolipoprotein E-defi cient mice // Circulation. — 2002. — Vol. 106, № 22. — P. 2767–2770.

66. Ouchi N., Kihara S., Arita Y. et al. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin // Circulation. — 1999. — Vol. 100, № 25. — P. 2473–2476.

67. Ouchi N., Kihara S., Arita Y. et al. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway // Circulation. — 2000. — Vol. 102, № 11. — P. 1296–1301.

68. Okamoto Y., Arita Y., Nishida M. et al. An adipocyte-derived plasma protein adiponectin, adheres to injured vascular walls // Horm. Metab. Res. — 2000. — Vol. 32, № 2. — P. 47–50.

69. Arita Y., Kihara S., Ouchi N. et al. Adipocyte-derived plasma protein adiponectin, acts as a platelet derived growth factor-BB binding protein and regulates growth factor-induced common postreceptor signal in vascular smooth muscle cell // Circulation. — 2002. — Vol. 105, № 24. — P. 2893–2898.

70. Ouchi N., Kihara S., Arita Y. et al. Adipocyte-derived plasma protein adiponectin, suppress lipid accumulation and class A scavenger receptor expression in human monocyte — derived macrophages // Circulation. — 2001. — Vol. 103, № 8. — P. 1057–1063.

71. Kumada M., Kihara S., Ouchi N. et al. Adiponectin specifi cally increases tissue inhibitor of metalloproteinase-1 through interleukin-10 expression in human macrophages // Circulation. — 2004. — Vol. 109, № 17. — P. 2046–2049.

72. Miller T., Borkowsky W., Dimeglio L. et al. Metabolic abnormalities and viral replication are associated with biomarkers of vascular dysfunction in HIV-infected children // HIV Med. — 2012. — Vol. 13, № 5. — P. 264–275.

73. Addabbo F., Nacci C., De Benedictis L. et al. Globular adiponectin counteracts VCAM-1-mediated monocyte adhesionvia AdipoR1/NF-κB/COX-2 signaling in human aortic endothelial cells // Am. J. Physiol. Endocrinol. Metab. — 2011. — Vol. 301, № 6. — E1143–1154.

74. Motoshima H., Wu X., Mahadev K., Goldstein B.J. et al. Adiponectin suppresses proliferation and superoxide generation and enhances eNOS activity in endothelial cells treated with oxidized LDL // Biochem. Biophys. Res. Commun. — 2004. — Vol. 315, № 2. — P. 264–271.

75. Chen H., Montagnani M., Funahashi T. et al. Adiponectin stimulates production of nitric oxide in vascular endothelial cells // J. Biol. Chem. — 2003. — Vol. 278, № 45. — P. 45021–45026.

76. Hattori Y., Suzuki M., Hattori S., Kasai K. Globular adiponectin upregulates nitric oxide production in vascular endothelial cells // Diabetologia. — 2003. — Vol. 46, № 11. — P. 1543–1549.

77. Scherer P.E. Adipose tissue: from lipid storage compartment to endocrine organ // Diabetes. — 2006. — Vol. 55, № 6. — P. 1537–1545.

78. Kadowaki T., Yamauchi T., Kubota N. The physiological and pathophysiological role of adiponectin and adiponectin receptors in the peripheral tissues and CNS // FEBS Lett. — 2008. — Vol. 582, № 1. — P. 74–80.

79. Kobayashi H., Ouchi N., Kihara S. et al. Selective suppression of endothelial cell apoptosis by the high molecular weight form of adiponectin // Circ. Res. — 2004. — Vol. 94, № 4. — Р. e27–e31.

80. Ouchi N., Kobayashi H., Kihara S. et al. Adiponectin stimulates angiogenesis by promoting cross-talk between AMP-activated protein kinase and Akt signaling in endothelial cells // J. Biol. Chem. — 2004. — Vol. 279, № 2. — P. 1304–1309.

81. Brakenhielm E., Veitonmaki N., Cao R. et al. Adiponectin-induced antiangiogenesis and antitumor activity involve caspasemediated endothelial cell apoptosis // Proc. Natl. Acad. Sci. USA. —2004. — Vol. 101, № 8. — P. 2476–2481.

82. Wu X., Mahadev K., Fuchsel L. et al. Adiponectin suppresses IkappaB kinase activation induced by tumor necrosis factor-alpha or high glucose in endothelial cells: role of cAMP and AMP kinase signaling // Am. J. Physiol. Endocrinol. Metab. — 2007. — Vol. 293, № 6. — Р. E1836–Е1844.

83. Mahadev K., Wu X., Donelly S. et al. Adiponectin inhibits vascular endothelial growth factor-induced migration of human coronary artery endothelial cells // Cardiovasc. Res. — 2008. — Vol. 78, № 2. — P. 376–384.

84. Morel F., Aninat C. The glutathione transferase kappa family // Drug. Metab. Rev. — 2011. — Vol. 43, № 2. — P. 281–291.

85. Lira F.S., Rosa J.C., Pimentel G.D. et al. Both adiponectin and interleukin-10 inhibit LPS-induced activation of the NF-kB pathway in 3T3-L1 adipocytes // Cytokine. — 2012. — Vol. 57, № 1. — P. 98–106.

86. You M., Rogers C.Q. Adiponectin: a key adipokine in alcoholic fatty liver // Exp. Biol. Med. (Maywood). — 2009. — Vol. 234, № 8. — P. 850–859.

87. Gaemers I.C., Stallen J.M., Kunne C. et al. Lipotoxicity and steatohepatitis in an overfed mouse model for non-alcoholic fatty liver disease // Biochim. Biophys. Acta. — 2011. — Vol. 1812, № 4. — P. 447–458.

88. Mollica M.P., Lionetti L., Putti R. et al. From chronic overfeeding to hepatic injury: role of endoplasmic reticulum stress and infl ammation // Nutr. Metab. Cardiovasc. Dis. — 2011. — Vol. 21, № 3. — P. 222–230.

89. Bredella M.A., Torriani M., Ghomi R.H. et al. Adiponectin is inversely associated with intramyocellular and intrahepatic lipids in obese premenopausal women // Obesity (Silver Spring). — 2011. — Vol. 19, № 5. — P. 911–916.

90. Sozio M.S., Liangpunsakul S., Crabb D. The role of lipid metabolism in the pathogenesis of alcoholic and nonalcoholic hepatic steatosis // Semin. Liver Dis. — 2010. — Vol. 30, № 4. — P. 378–390.

91. Larter C.Z., Chitturi S., Heydet D., Farrell G.C. A fresh look at NASH pathogenesis. Part 1: the metabolic movers // J. Gastroenterol. Hepatol. — 2010. — Vol. 25, № 4. — P. 672–690.

92. Hsu C.S., Liu C.H., Wang C.C. et al. Impact of hepatitis B virus infection on metabolic profiles and modifying factors // J. Viral. Hepat. — 2012. — Vol. 19, № 2. — Р. e48–е57.

93. Polyzos S.A., Kountouras J., Zavos C., Tsiaousi E. The role of adiponectin in the pathogenesis and treatment of non-alcoholic fatty liver disease // Diabetes Obes. Metab. — 2010. — Vol. 12, № 5. — P. 365–383.

94. Liang F., Kume S., Koya D. SIRT1 and insulin resistance // Nat. Rev. Endocrinol. — 2009. — Vol. 5, № 7. — P. 367–373.

95. Petta S., Amato M.C., Di Marco V. et al. Visceral adiposity index is associated with signifi cant fi brosis in patients with non-alcoholic fatty liver disease // Aliment. Pharmacol. Ther. — 2012. — ol. 35, № 2. — P. 238–247.

96. Targher G., Rossi A.P., Zamboni G.A. et al. Pancreatic fat accumulation and its relationship with liver fat content and other fat depots in obese individuals // J. Endocrinol. Invest. — 2012. — Vol. 35, № 8. — P. 748–753.

97. Mori Y., Oana F., Matsuzawa A. et al. Short-term effect of bezafibrate on the expression of adiponectin mRNA in the adipose tissues: a study in spontaneously type 2 diabetic rats with visceral obesity // Endocrine. — 2004. — Vol. 25, № 3. — P. 247–251.

98. Koh K.K., Quon M.J., Shin K.C. et al. Significant differential effects of omega-3 fatty acids and fenofibrate in patients with hypertriglyceridemia // Atherosclerosis. — 2012. — Vol. 220, № 2. — P. 537–544.

99. Sofer E., Boaz M., Matas Z. et al. Treatment with insulin sensitizer metformin improves arterial properties, metabolic parameters, and liver function in patients with nonalcoholic fatty liver disease: a randomized, placebo-controlled trial // Metabolism. — 2011. — Vol. 60, № 9. — P. 1278–1284.

100. Matafome P., Louro T., Rodrigues L. et al. Metformin and atorvastatin combination further protect the liver in type 2 diabetes with hyperlipidaemia // Diabetes Metab. Res. Rev. — 2011. — Vol. 27, № 1. — P. 54–62.

101. de Pablos-Velasco P. Pioglitazone: beyond glucose control // Expert. Rev. Cardiovasc. Ther. — 2010. — Vol. 8, № 8. — P. 1057–1067.

102. Waki H., Yamauchi T., Kadowaki T. Regulation of differentiation and hypertrophy of adipocytes and adipokine network by PPARgamma // Nippon Rinsho. — 2010. — Vol. 68, № 2. — P. 210–216.

103. Perez A., Jacks R., Arora V. et al. Effects of pioglitazone and metformin fi xed-dose combination therapy on cardiovascular risk markers of infl ammation and lipid profi le compared with pioglitazone and metformin monotherapy in patients with type 2 diabetes // J. Clin. Hypertens. (Greenwich). — 2010. — Vol. 12, № 12. — P. 973–982.

104. Sam S., Haffner S., Davidson M.H. et al. Pioglitazone-mediated changes in lipoprotein particle composition are predicted by changes in adiponectin level in type 2 diabetes. J. Clin. Endocrinol. Metab. — 2012. — Vol. 97, № 1. — Р. E110–Е114.

105. Yki-Järvinen H. Thiazolidinediones and the liver in humans // Curr. Opin. Lipidol. — 2009. — Vol. 20, № 6. — P. 477–483.

106. Li M., Xu A., Lam K.S. et al. Impact of combination therapy with amlodipine and atorvastatin on plasma adiponectin levels in hypertensive patients with coronary artery disease: combination therapy and adiponectin // Postgrad. Med. — 2011. — Vol. 123, № 6. — P. 66–71.

107. Miyata Y., Tanaka H., Shimada A. Regulation of adipocytokine secretion and adipocyte hypertrophy by polymethoxyfl a-vonoids, nobiletin and tangeretin // Life Sci. — 2011. — Vol. 88, № 13–14. — P. 613–618.

108. Дильман В.М. Четыре модели медицины. — Л.: Медицина, 1987. — 287 с. / Dilman V.M. Four models of medicine. — Leningrad: Medicine, 1987. – 287 p. [Russian].

109. Dilman V.M., Berstein L.M. Hypothalamic mechanisms of aging and of specifi c age pathology. IV. Sensitivity threshold of hypothalamo-pituitary complex to homeostatic stimuli in the thyroid system // Exp. Gerontol. — 1979. — Vol. 14, № 5. — P. 225–230.

110. Дильман В.М., Остроумова М.Н., Благосклонная Я.В. Метаболическая иммунодепрессия. Нормализующее влияние фенформина // Физиология человека. — 1977. — Т. 3, № 4. — С. 579–586. / Dilman V.M., Ostroumova M.N., Blagosklonnaya Ya.V. Metabolic immunodepression. Normalizing effect of fenformin // Human Physiology [Fisiologiya Cheloveka]. — 1977. — Vol. 3, № 4. — P. 579–586 [Russian].

111. Barb D., Pazaitou-Panayiotou K., Mantzoros C.S. Adiponectin: a link between obesity and cancer // Expert Opin. Investig. Drugs. — 2006. — Vol. 15, № 8. — P. 917–933.

112. Yokota T., Oritani K., Takahashi I. et al. Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages // Blood. — 2000. — Vol. 96, № 5. — P. 1723–1732.

113. Kang J.H., Lee Y.Y., Yu B.Y. et al. Adiponectin induces growth arrest and apoptosis of MDA-MB-231 breast cancer cell // Arch. Pharm. Res. — 2005. — Vol. 28, № 11. — P. 1263–1269.

114. Dieudonne M.N., Bussiere M., Dos Santos E. et al. Adiponectin mediates antiproliferative and apoptotic responses in human MCF7 breast cancer cells // Biochem. Biophys. Res. Commun. — 2006. — Vol. 345, № 1. — P. 271–279.

115. Bub J.D., Miyazaki T., Iwamoto Y. Adiponectin as a growth inhibitor in prostate cancer cells // Biochem. Biophys. Res. Commun. — 2006. — Vol. 340, № 4. — P. 1158–1166.

116. Wang Y., Lam K.S., Xu J.Y. et al. Adiponectin inhibits cell proliferation by interacting with several growth factors in an oligomerization-dependent manner // J. Biol. Chem. — 2005. — Vol. 280, № 18. — P. 18341–18347.

117. Miyazaki T., Bub J.D., Uzuki M., Iwamoto Y. Adiponectin activates c-Jun NH2-terminal kinase and inhibits signal transducer and activator of transcription 3 // Biochem. Biophys. Res. Commun. — 2005. — Vol. 333, № 1. — P. 79–87.

118. Saitoh M., Nagai K., Nakagawa K. et al. Adenosine induces apoptosis in the human gastric cancer cells via an intrinsic pathway relevant to activation of AMP-activated protein kinase // Biochem. Pharmacol. — 2004. — Vol. 67, № 10. — P. 2005–2011.


Дополнительные файлы

Для цитирования: Парфенова Н.С., Танянский Д.А. АДИПОНЕКТИН: БЛАГОПРИЯТНОЕ ВОЗДЕЙСТВИЕ НА МЕТАБОЛИЧЕСКИЕ И СЕРДЕЧНО-СОСУДИСТЫЕ НАРУШЕНИЯ. Артериальная гипертензия. 2013;19(1):84-96. https://doi.org/10.18705/1607-419X-2013-19-1-84-96

For citation: Parfenova N.S., Tanyanskiy D.A. ADIPONECTIN: BENEFICIAL EFFECTS ON METABOLIC AND CARDIOVASCULAR DYSFUNCTIONS. "Arterial’naya Gipertenziya" ("Arterial Hypertension"). 2013;19(1):84-96. (In Russ.) https://doi.org/10.18705/1607-419X-2013-19-1-84-96

Просмотров: 393

Обратные ссылки

  • Обратные ссылки не определены.


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1607-419X (Print)
ISSN 2411-8524 (Online)